Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H13N.ClH |
| Molecular Weight | 195.689 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(CC#C)CC1=CC=CC=C1
InChI
InChIKey=BCXCABRDBBWWGY-UHFFFAOYSA-N
InChI=1S/C11H13N.ClH/c1-3-9-12(2)10-11-7-5-4-6-8-11;/h1,4-8H,9-10H2,2H3;1H
| Molecular Formula | C11H13N |
| Molecular Weight | 159.2276 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2039 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9564606 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Eutonyl Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
75 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/490428/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PARGYLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
272 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/490428/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PARGYLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/490428/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PARGYLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/8114614/ Page: 7.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8114614/ Page: 7.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8114614/ Page: 7.0 |
yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/11306107/ Page: 10.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11306107/ Page: 10.0 |
yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction. | 2015-03-25 |
|
| Acute effects of resveratrol to enhance cocaine-induced dopamine neurotransmission in the striatum. | 2013-05-10 |
|
| Oxidative stress by monoamine oxidases is causally involved in myofiber damage in muscular dystrophy. | 2010-11-01 |
|
| Alterations in hippocampal serotonergic and INSR function in streptozotocin induced diabetic rats exposed to stress: neuroprotective role of pyridoxine and Aegle marmelose. | 2010-09-25 |
|
| IRAK-M regulates chromatin remodeling in lung macrophages during experimental sepsis. | 2010-06-16 |
|
| Clinical review: immunomodulatory effects of dopamine in general inflammation. | 2004-12 |
|
| Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. | 2004-05-25 |
|
| GABAergic and dopaminergic systems may be involved in seizures induced by pyrimethamine in mice. | 1994-10 |
|
| The MAO-B inhibitor deprenyl, but not the MAO-A inhibitor clorgyline, potentiates the neurotoxicity of p-chloroamphetamine. | 1994-07-11 |
|
| The involvement of noradrenaline, 5-hydroxytryptamine and acetylcholine in imipramine-induced seizures in mice. | 1993-10-15 |
|
| Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. | 1987-09 |
|
| Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys. | 1987 |
|
| [Effects of pentoxifylline on 5-hydroxytryptamine in the mouse brain]. | 1985-11 |
|
| Chronic but not acute treatment with antidepressants enhances the electroconvulsive seizure response in rats. | 1985-10 |
|
| Treatment with clorgyline and pargyline differentially decreases clonidine-induced hypotension and bradycardia. | 1984-09 |
|
| Pargyline-induced mania in primary affective disorder: case report. | 1983-01 |
|
| The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. | 1982-11-15 |
|
| Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients. | 1982-05 |
|
| Determination of the role of serotonergic and cholinergic systems in apomorphine--induced aggressiveness in rats. | 1979-03-01 |
|
| Testosterone-attenuated stereotype and hyperactivity induced by beta-phenylethylamine in pargyline-pretreated rats. | 1978-08 |
|
| Role of the sympathetic nervous system in daunomycin-induced arrhythmia in the monkey. | 1970-07 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3208065
Curator's Comment: The two molecular forms of monoamine oxidase (MAO), MAO-A and MAO-B, were determined quantitatively in discrete regions of the human brain at autopsy, and in cerebral microvessels, choroid plexus and liver samples from the same subjects. MAO was assessed by specific[3H] pargyline binding, which is stoichiometric and irreversible, and by measuring the rate of oxidation of several MAO substrates. Basal ganglia structures (caudate, putamen, globus pallidus and substantia nigra) and hippocampus had about twice the levels of MAO that were present in the cerebral cortex and cerebellum. Cerebral microvessels, which constitute the blood-brain barrier, had minimal MAO, while the choroid plexus, which constitutes the blood-cerebrospinal fluid barrier, and the liver had higher MAO levels than any brain region. The vast majority of MAO (80-95%) in these tissues was of the B type, except in microvessels, where total MAO activity was low. Specific [3H]pargyline binding correlated well with the oxidation rates for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and benzylamine in all tissues. Both specific [3H]pargyline binding and the rate of oxidation of MAO substrates increased with age.
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:21:35 GMT 2025
by
admin
on
Mon Mar 31 18:21:35 GMT 2025
|
| Record UNII |
W70V6I2OMY
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C667
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
||
|
NCI_THESAURUS |
C270
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID1044647
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
PRIMARY | |||
|
206-175-1
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
PRIMARY | |||
|
m8412
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
PRIMARY | Merck Index | ||
|
82069
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
PRIMARY | RxNorm | ||
|
DBSALT000304
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
PRIMARY | |||
|
100000085538
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
PRIMARY | |||
|
CHEMBL673
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
PRIMARY | |||
|
9373
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
PRIMARY | |||
|
SUB03653MIG
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
PRIMARY | |||
|
43798
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
PRIMARY | |||
|
C66323
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
PRIMARY | |||
|
W70V6I2OMY
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
PRIMARY | |||
|
306-07-0
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |